Northern Trust
BTAI

Northern Trust’s BioXcel Therapeutics BTAI Stock Holding History

Northern Trust’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.4K Buy
56,318
+20,005
+55% +$23.4K ﹤0.01% 4177
2026
Q1 		$48.7K Sell
36,313
-2,057
-5% -$3.39K ﹤0.01% 4250
2025
Q4 		$61.4K Buy
38,370
+637
+2% +$1.31K ﹤0.01% 4237
2025
Q3 		$96.6K Buy
+37,733
New +$119K ﹤0.01% 4148
2025
Q1 		– Sell
-4,619
Closed -$27.6K – 4431
2024
Q4 		$27.6K Buy
4,619
+2,072
+81% +$17.3K ﹤0.01% 4346
2024
Q3 		$24.9K Sell
2,547
-9,638
-79% -$130K ﹤0.01% 4317
2024
Q2 		$250K Sell
12,185
-1,040
-8% -$34.8K ﹤0.01% 3776
2024
Q1 		$597K Sell
13,225
-862
-6% -$41.1K ﹤0.01% 3507
2023
Q4 		$665K Sell
14,087
-17
-0.1% -$945 ﹤0.01% 3447
2023
Q3 		$571K Sell
14,104
-1,153
-8% -$117K ﹤0.01% 3478
2023
Q2 		$1.63M Buy
15,257
+2,028
+15% +$675K ﹤0.01% 3130
2023
Q1 		$3.95M Sell
13,229
-251
-2% -$107K ﹤0.01% 2598
2022
Q4 		$4.63M Buy
13,480
+488
+4% +$118K ﹤0.01% 2531
2022
Q3 		$2.46M Buy
12,992
+118
+0.9% +$27.4K ﹤0.01% 2904
2022
Q2 		$2.72M Buy
12,874
+711
+6% +$150K ﹤0.01% 2881
2022
Q1 		$4.07M Buy
12,163
+81
+0.7% +$23.5K ﹤0.01% 2707
2021
Q4 		$3.93M Buy
12,082
+201
+2% +$86.2K ﹤0.01% 2836
2021
Q3 		$5.77M Buy
11,881
+583
+5% +$256K ﹤0.01% 2634
2021
Q2 		$5.25M Buy
11,298
+923
+9% +$503K ﹤0.01% 2805
2021
Q1 		$7.17M Sell
10,375
-1,342
-11% -$1.08M ﹤0.01% 2516
2020
Q4 		$8.66M Sell
11,717
-150
-1% -$117K ﹤0.01% 2338
2020
Q3 		$8.23M Buy
11,867
+1,025
+9% +$770K ﹤0.01% 2223
2020
Q2 		$9.2M Buy
10,842
+2,784
+35% +$1.82M ﹤0.01% 2147
2020
Q1 		$2.88M Buy
8,058
+664
+9% +$239K ﹤0.01% 2639
2019
Q4 		$1.73M Buy
7,394
+421
+6% +$42.3K ﹤0.01% 3206
2019
Q3 		$786K Buy
6,973
+4,234
+155% +$668K ﹤0.01% 3452
2019
Q2 		$481K Buy
2,739
+1,951
+248% +$330K ﹤0.01% 3560
2019
Q1 		$125K Buy
+788
New +$97.2K ﹤0.01% 3873

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust's BTAI Position: Q2 2026 in Review

Northern Trust increased its BioXcel Therapeutics (BTAI) stake by 55% in Q2 2026, buying an estimated $23.4K and bringing the position to 56,318 shares worth $79.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4177.

Northern Trust first reported a position in BTAI in Q1 2019 and has held it in 28 quarters since. The position peaked at $9.2M in Q2 2020. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Northern Trust held 56,318 shares of BioXcel Therapeutics worth $79.4K as of Q2 2026.
  • Northern Trust bought 20,005 BioXcel Therapeutics shares in Q2 2026, an estimated $23.4K.
  • BioXcel Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4177 holding.
  • Northern Trust first reported a position in BioXcel Therapeutics in Q1 2019 and has held it in 28 quarters since.
  • Northern Trust's BioXcel Therapeutics position peaked at $9.2M in Q2 2020.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.